Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$319.66 USD

319.66
1,467,828

+2.18 (0.69%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

    Amgen Files for Approval of Osteoporosis Drug in Japan

    Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

      Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

      Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

        Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study

        Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.

          Stock Market News for December 08, 2016

          The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

            Arpita Dutt headshot

            Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus

            This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.

              AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

              AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.

                Amgen/Allergan File for EU Approval of Avastin Biosimilar

                Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                  Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                  Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

                    Momenta/Shire's Humira Biosimilar Meets Study Objective

                    Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.

                      Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab

                      Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.

                        Arpita Dutt headshot

                        Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno

                        With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?

                          The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                          The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                            Sheraz Mian headshot

                            Top Research Reports for Cisco, Amgen & NextEra Energy

                            Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).

                              Eric Dutram headshot

                              Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?

                              In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.

                                Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences

                                Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences

                                  Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen

                                  Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen

                                    Arpita Dutt headshot

                                    Fundamentals Remain Strong in the Pharma Sector

                                    We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.

                                      Pricing Issues Continue to Weigh on the Pharma Sector

                                      With generics and biosimilars on the rise, many pharma companies are looking towards new products to pick up the pace and make up for lost sales.

                                        Arpita Dutt headshot

                                        Pharma Industry Outlook - November 2016

                                        It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.

                                          Stock Market News for October 12, 2016

                                          Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday

                                            6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings

                                            A number of healthcare companies are recording improvements in their financial numbers.

                                              Stock Market News for September 15, 2016

                                              Both the Dow and the S&P 500 closed in the red on Wednesday, thanks to a slump in crude-oil prices

                                                Sheraz Mian headshot

                                                Top Research Reports for September 2, 2016

                                                Today's must-read reports are for Amgen (AMGN), HSBC (HSBC) and Broadcom (AVGO).

                                                  Stock Market News for August 09, 2016

                                                  Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks